Tonix Pharmaceuticals Expands Pre☆→clinical Pipeline with Triple Reup$γ₹take Inhibitor, TNX-1600, for the Treatmeσ©¥↑nt of PTSD
Tonix Pharmaceuticals Holding Corp., a clini•§£cal-stage biopharmaceutical company, announced toλ♥day an exclusive agreement to in-★>license a triple reuptake in♥ε₹hibitor (TRI), TNX-1600 (formerly D-5≥Ωπ78), to treat posttrauδ¥↔<matic stress disorder (PTSD) and potent•<→ially other central nerv$£ous system (CNS) disorders. T&φ≥he compound was deveφ€loped and pharmacologically charΩ$acterized by Aloke Dutta, Ph.D., professor of Phεarmaceutical Sciences at Wayne Stat"≈ e University, with fuδ€✔nding from a National Institutes of Health gr±§$↔ant (grant number MH084888), and©∑ the patents covering the compounds wereλσ licensed to TRImara☆₹•n Pharma, Inc. (TRImaran). Th§€e transaction announced today is a lice Ω"×nse agreement with Wayne State ¶and an asset acquisition with TR★♥ Imaran.“We are excited to expand our pipeline a♣ ← nd are looking forward to developing ≠φTNX-1600 as a potential∑& treatment for PTSD,” said ←©≈≤Seth Lederman, M.D., Tonix's Pre>↓•sident and Chief Executive Officer. “↑±We plan to utilize our↓₩♦ clinical experience in PTSD to 'γ×evaluate the therapeutic b₹ enefit of TNX-1600. PTSD is a≤• heterogeneous condition, so we believe differe¥πε×nt PTSD patients may respond to different mφ&edicines. In some cases, more than one drug will ♣πbe required for effective treatm≠φ∏ent. TNX-1600 is our third drug candi≥≥¥date in development f₹•or PTSD. Our most advanced candidate is TNX->©♠102 SL, which is in Phase 3 development. β↕✔♣We are also developing TNX★✘-601 which is enterin£ ♣g a Phase 1 trial imminently. TNX-1600 is in t$☆←₽he pre-IND phase of deve÷β§₩lopment with encouraging♥♥ data from animal models of PTSD.”Frank Bymaste "r, Chief Scientific Officer and co-found→✔₹er of TRImaran Pharma Inc. said, “T↓≠←NX-1600 is a novel TRI that inhibits sim¶ ultaneously the reuptake of three key neurotransγ¶¥mitters: serotonin, norepine★ ¶phrine and dopamine. Each of these three neu★✘★'rotransmitters plays a key modulatory role in<¶ many CNS processes. Inhibit ±ing reuptake of all three may providφ≠e an effective treatment for P<© ♠TSD.”According to Dr. δπAloke Dutta, “We have developed an innovative trλ₽×iple reuptake inhibito←αγr, D-578, based on a unique pyr÷>&♣an molecular scaffold to address the curr←ent therapeutic needs for P™∏₹TSD and other neurologic∏♣π×al disorders. Based on our preliminary data, ±'we expect a pharmacological synergy from σε£their potent modulatory effect on the level of mo™γ♠noamine neurotransmitt" ♦ers in the brain which should f♠§acilitate effective treatment of th$ >ese disorders.”Under the term♦↓✘s of the agreement, Tonix ha↕<♣s been granted an exclusive ✘≤♠license from Wayne State University fo€₩↑r technology and patents related to T¥♥±NX-1600 and other pyran-bas♠★←₽ed compounds. Another member×&♦σ of the class, D-473, has a₹₩≥lso shown effects in a≥≈↔♦ rodent model of depression.the 201§☆∑δ9 Asia-pacific Pharmaceutical IP Leader Su↑↔÷<mmit will be held in Beijing on November™£✔• 14-15, and will attra♠↑ct more than 500 industry experts from domestic a♣nd foreign pharmaceutical companies, biotechno∑₽logy companies, governments, asso∏✘±•ciations, law firms, intellectualβ>α property agents and other co§ε₽mpanies to attend. 2019 Asia-pacific₽γ'£ Pharmaceutical IP Leader Summi"✔δt Official regisΩα®tration and consultation c≥×hannels:Contact:AnnPhone: 021-65650305Email♣★:Marketing@zenseegroup.comhttp:"¥←//en.zenseegroup.com/p/51093€≥∞ 4/